Researchers at Vanderbilt University Medical Center have developed a new method for identifying drugs for the repurposing trials that can lead to new indications for drugs already in use.

Analyzing electronic health records (EHR) of 9,748 patients diagnosed with COVID-19, Cosmin Bejan, PhD, Elizabeth Phillips, MD, and colleagues at Vanderbilt University Medical Center asked whether COVID disease severity correlated with any drugs that happened to be taken by these patients in the months leading up to their diagnosis.

Vanderbilt University Medical Center (VUMC) has been named Data Coordinating Center (DCC) for a nationwide platform of studies aimed at “repurposing” existing drugs to treat mild to moderate symptoms of COVID-19.

Vanderbilt University Medical Center is attracting international attention for its proposal to repurpose existing drugs for new uses in ways that can dramatically improve access to medicines by billions of people throughout the world.

The John D. and Catherine T. MacArthur Foundation today unveiled a grant proposal from Vanderbilt University Medical Center (VUMC) as one of the highest-scoring proposals, designated as the “Top 100,” in its 100&Change competition for a single $100 million grant to help solve one of the world’s most critical societal challenges.

An inexpensive generic drug once used to prevent gastrointestinal ulcers in people taking daily NSAIDs protects against C. diff infection in mice.